Press Releases

ProductLife Group Becomes PLG | Advanced Intelligence for Life Sciences

Admin — Mon, 28 Sep 2026 08:13:43 GMT

The consolidation of 26 businesses, acquired over six years, into one identity — now expressed through a new brand: PLG, Advanced Intelligence For Life Sciences

Dr. James Burt Joins ProductLife Group as CEO

ADMINUSER — Fri, 20 Mar 2026 04:00:00 GMT

Paris, March 16th, 2026

ProductLife Group (PLG), a global provider of consulting and outsourcing services for the life sciences industry, announced the appointment of Dr. James Burt as Chief Executive Officer.

Dr. Burt brings more than 20 years of international leadership experience across the pharmaceutical value chain, including generic, biosimilar, orphan and value-added medicines. His career reflects a strong track record of leading global organizations, scaling operations and driving strategic transformation in complex healthcare markets.

Most recently, Dr. Burt served as Group CEO of Pharmanovia, where he led a major strategic transformation and delivered significant business growth. Prior to that, he spent over a decade at Accord Healthcare, most recently as Executive Vice President for Europe, the Middle East and Africa, where he oversaw a €750 million P&L and led a team of approximately 2,500 colleagues.

Dr. Burt holds a Ph.D. in Biochemical Engineering from the University of Birmingham and has been actively involved in industry leadership initiatives, including serving as Vice President of Medicines for Europe and Chair of the Value-Added Medicines Group.

This appointment follows a transition period during which Shaun Chilton served as Executive Chairman, supporting the organization’s continuity and helping position ProductLife Group for its next phase of development. He will continue to support the Group in his role as Chairman alongside Dr. Burt.

Dr. Burt’s arrival comes at an important moment for ProductLife Group as the company continues to expand its global footprint and strengthen its capabilities across regulatory, clinical, quality and digital services, supporting pharmaceutical, biotech and medical device companies worldwide.

Dr. Burt commented:

"ProductLife Group has established itself as a trusted partner to the life sciences industry. I am excited to join the organization and work alongside its teams to further advance the company’s capabilities, support its strategic development and continue delivering value to clients and patients worldwide."

This leadership transition marks a new phase of growth for ProductLife Group as it continues to expand its global capabilities and support clients across the life sciences ecosystem.

About ProductLife Group ProductLife Group (PLG) is a global provider of consulting and outsourcing services for the life sciences industry, delivering end-to-end support across the entire product lifecycle. With a presence in 150+ countries, operations in 50+ countries, and a team of over 2,000 professionals, PLG acts as a one-stop partner for pharmaceutical, biotechnology, medical device, nutrition and cosmetics companies.

Media contact: Annalisa Merola | Corporate Communication Director - ProductLife Group amerola@productlife-group.com

PLG Partners with Alteryx on Life Sciences Data Migration

Fabiana Nichetti — Thu, 22 Jan 2026 05:00:00 GMT

ProductLife Group (PLG), a global provider of regulatory and digital transformation solutions for the life sciences industry, is proud to announce a strategic partnership with Alteryx, a leading AI and data analytics company.

Through this collaboration, PLG’s Consulting & Digital Business Unit will leverage the power of the Alteryx One platform to accelerate compliant data migration and enhance data readiness across the life sciences sector, supporting clients in their digital transformation journey from compliance to intelligence.

Addressing Complexity with Innovation

Data migration in life sciences often means navigating complex, highly regulated environments. Integrating legacy systems, ensuring GxP compliance, and maintaining complete data integrity can turn each project into a costly and time-consuming challenge.

With Alteryx’s AI and analytics automation technology, PLG brings a new approach — combining advanced data analytics, automation, and compliance expertise to streamline migration workflows, reduce manual intervention, and enable transparent, inspection-ready data processes.

From Compliance to Data Intelligence

This partnership enhances PLG’s ability to support companies that aim to move beyond compliance toward data-driven decision-making and AI enablement. The joint solution allows organizations to:

Automate complex data migration activities with traceability and validation.
Strengthen data integrity and compliance through configurable, auditable processes.
Accelerate digital transformation and prepare data for AI, predictive analytics, and advanced business insights.

A Shared Commitment to Innovation

“This partnership marks an important step in how ProductLife Group supports life sciences companies in their digital evolution” - said Nick Larsen, Director of Data, AI & Migrations - “By combining Alteryx’s automation and analytics capabilities with our regulatory and compliance expertise, we empower clients to unlock the full potential of their data while ensuring it remains compliant, secure, and actionable.” “We are delighted to collaborate with ProductLife Group,” Remco den Heijer added . “Together, we deliver powerful, AI-ready solutions that simplify data migration and analytics, enabling life sciences organizations to innovate safely and efficiently.”

Empowering Digital Transformation Across Life Sciences

As part of the PLG Consulting & Digital Business Unit, this partnership reinforces PLG’s commitment to enabling digital excellence and compliance across R&D, Quality, Regulatory Affairs, and Manufacturing. Through scalable frameworks, proprietary validation accelerators, and cutting-edge partnerships like this one, PLG continues to guide the life sciences industry toward a smarter, data-driven, and compliant future.

Get in Touch

ProductLife Group Expands in Japan | Local Expertise & Support

Giulia Maffei — Thu, 04 Sep 2025 04:00:00 GMT

4 September 2025 ProductLife Group ( PLG) is proud to announce the opening of its newest office in Japan, reinforcing its commitment to meeting evolving client needs and market demands.

This expansion enhances capacity, strengthens our regional and global network, and enables seamless collaboration to support additional markets and services.

As life sciences companies increasingly seek global expertise with localized talent, PLG’s growth ensures clients receive tailored solutions backed by deep industry knowledge and an interconnected team across the globe.

“Expanding into new global markets is not just a growth strategy—it’s a commitment to accelerating the development of life-changing drugs and devices,” said Xavier Duburcq, CEO, PLG. “By broadening our reach, we’re able to bring innovative solutions to more patients, faster, and deliver on our promise to improve health outcomes worldwide.”

“This expansion is a milestone in our journey to deliver world-class expertise with local insights,” said Tanya van der Wall, Managing Director, JAPAC.

“Our strengthened presence in Japan/Asia Pacific (JAPAC) allows us to elevate client services and foster collaboration across global and regional markets. This office will serve as a hub for local expertise and talent, strategy, and partnership, ensuring continued growth and success."

Initial focus and expertise will be safety & vigilance and regulatory affairs including case processing, signal detection, literature surveillance, medical technical writing, regulatory strategy and new product registrations (J-NDA) approval for clinical trials, lifecycle maintenance and compliance, and PMDA consultations. The office will host local experts with both English and Japanese language proficiencies.

Recipharm and PLG announce strategic partnership

ADMINUSER — Tue, 13 May 2025 04:00:00 GMT

13 May 2025

Combines Recipharm’s development and manufacturing capabilities with PLG’s product development expertise and regulatory affairs experience
Reduces timelines to first-in-human clinical trials and market approvals, through the combined expertise of two leaders in product development
Benefits patients suffering from diseases with high unmet medical needs

Recipharm, a leading global contract development and manufacturing organisation (CDMO), and ProductLife Group (PLG), a global provider product development and regulatory affairs services, announced a strategic collaboration aimed at supporting (bio)pharmaceutical companies in accelerating time to clinical trials and market approval while reducing supply chain, compliance, and regulatory challenges during product development.

This agreement brings together Recipharm’s fully integrated development and manufacturing capabilities across small molecules, traditional biologics and advanced therapies medicinal products (ATMPs) with PLG’s deep expertise in product development, regulatory affairs and market access. By combining forces, the two companies will ensure customers receive comprehensive support from early-stage development to approval and market access, which will result in earlier availability of medicines to the market.

For Recipharm’s customers, the partnership offers immediate access to PLG’s product development expertise as well as their global regulatory affairs, pharmacovigilance and market access experience. With PLG integrated into Recipharm’s service offering, pharma and biotech companies can now begin with the end in mind, aligning product development, regulatory and market access plans in early stages of product development while maintaining both control and foresight throughout scale-up and manufacturing.

For PLG’s clients, the collaboration opens access to Recipharm’s manufacturing infrastructure, including integrated and intelligent development, manufacturing support for faster and more cost-effective development, and predictive models for biologics production and release, offering a high-value solution tailored to global needs.

Greg Behar, Recipharm’s CEO explains:

"This partnership brings together Recipharm’s development and manufacturing expertise, with PLG’s 2,000 regulatory experts, operating across 150 countries. By integrating scientific, regulatory, operational and commercial strategy from the outset we help our customers move faster, avoid costly delays and build confidence that their product submissions will meet and exceed, agency requirements, for critical medicines worldwide. "

Xavier Duburcq, PLG’s CEO confirms: "As regulatory complexity grows, our clients need integrated solutions that connect strategy and execution. With Recipharm’s 700 product development experts and over 400 projects delivered annually, this partnership allows us to embed regulatory thinking directly into product development and operational planning. Together, we help our clients ensure compliance and build stronger submissions from the start."

This collaboration represents a powerful alignment of capabilities designed to address the growing complexity of global regulatory requirements. By uniting PLG’s regulatory depth with Recipharm’s robust development and manufacturing infrastructure, clients gain a streamlined pathway from early development through to submission and launch. Together, the two companies offer a unified approach that supports innovation, reduces time to market and meets the demands of a rapidly evolving global regulatory environment.

For more information

About Recipharm Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) employing over 5,000 employees worldwide. Recipharm provides manufacturing services of pharmaceuticals in various dosage forms, including sterile fill & finish, oral solid dosage and biologics; clinical trial material development and manufacturing services; and pharmaceutical product development. Its ReciBioPharm division works with customers to develop and commercialise advanced therapy medicinal products (ATMPs): pre-clinical to clinical development, commercial development and manufacture for new biological modalities, encompassing technologies based on live viruses and viral vectors, live-microbial biopharmaceutical products, nucleic acid-based mRNA and plasmid DNA production.

Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. It operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden and the US and is headquartered in Stockholm, Sweden.

For more information on Recipharm, please visit us here and here.

Media contact: Guenaelle Holloway, Head of communications
Guenaelle.Holloway@recipharm.com
+44 7730 303 708

About ProductLife Group: ProductLife Group’s mission is to support patient access to safe and effective healthcare solutions by delivering worldwide consulting and outsourcing services through the entire product life cycle. Combining local expertise with global reach spanning more than 150 countries, PLG is the Life Sciences Industry reference strategic partner for the development, market introduction and life cycle management of product portfolios, and related business and digital transformation. With a goal of continuously improving the value delivered to teams and clients, PLG is committed to long-term partnership, innovation, flexibility, and cost efficiency.

For more information, visit the website
Media contact: Fabrice Galzin
ProductLife Group Head of Marketing
fgalzin@productlife-group.com

Commercial Eyes is partnering with ANDHealth.

ADMINUSER — Mon, 28 Apr 2025 04:00:00 GMT

28th April 2025 – Australia’s digital and connected health sector will have access to even greater commercialisation support with pharmaceutical and medtech commercialisation company Commercial Eyes, part of ProductLife Group (PLG), signing a deal to become a core partner of ANDHealth.

The strategic partnership brings together ANDHealth's proven expertise in scaling digital health businesses with Commercial Eyes' deep knowledge of regulatory frameworks and market access strategies, creating a powerful alliance to support Australia's growing digital health ecosystem.

Bronwyn Le Grice, ANDHealth Chief Executive Officer, said that the partnership would deliver real benefits for digital and connected health companies at a time when the sector is growing rapidly, and companies are looking to commercialise innovative solutions.

"We are delighted to welcome Commercial Eyes as our newest Core Partner," Ms Le Grice said.

"We have a strong pipeline of more than 1,000 digital and connected health companies that work with us, all at various stages of maturity. The extensive experience Commercial Eyes has in market access pathways, compliance, patient programs, regulatory frameworks and risk management will be invaluable to those companies and strengthen our offer across the entire commercialisation pathway, from ‘idea to exit’.

“Their connections into the EU in particular through their Paris based parent company ProductLife Group will also support those Australian companies looking to expand internationally.

“Together, we will strengthen the commercialisation pipeline for Australian digital and connected health SMEs, creating jobs, attracting investment, and improving patient outcomes," Ms. Le Grice said.

“We have been involved with ANDHealth in various ways over many years, including providing masterclasses to different cohorts on the areas of market research, access and intelligence, as well as working directly with cohort companies to solve some of their major challenges” said Commercial Eyes’ Country Managing Director, Tanya van der Wall.

“As part of ProductLife Group, we advise and connect Australian companies with a network of experts to support their global growth ambitions in Europe, the US, JAPAC and beyond which provides opportunities for Australian innovators to scale globally while retaining their base of operations in Australia.”

“We are inspired by the creativity, sophistication and overall professionalism of the cohort companies, backed by an exemplary ANDHealth team. As a Core Partner, we look forward to supporting them and the wider ANDHealth network of 1000+ innovators and emerging technologies.”

To arrange interviews, please contact: Media Contact
James Howe
General Manager, Corporate Affairs
Mobile: 0488 065 058
Email: james@andhealth.com.au

About ANDHealth

ANDHealth is Australia’s only organisation specialised in the commercialisation of evidence-based digital health technologies. ANDHealth’s globally unique cooperative commercialisation model has led to significant growth within Australia’s nascent digital health sector and continues to be a driving force for the development of Australia’s capability in evidence-based, regulated, digital health technologies.

ANDHealth is now one of Australia’s leading health technology commercialisation organisations, ranking in the Australian Financial Review’s Top 10 Most Innovative Companies in Health in 2023. Companies participating in its flagship ANDHealth+ program raised $19.70 in new capital and generated $6.70 in new revenues for every dollar invested. ANDHealth manages over $30M in public and private commitments to digital health commercialisation and provides specialist support to a further $100M of funding managed by Brandon Capital. www.andhealth.com.au

About Commercial Eyes
Commercial Eyes is Australia’s leading pharmaceutical and medical device commercialisation company. With 23 years of experience, more than 900 pharmaceutical, medical device, diagnostic, and consumer healthcare companies rely on our expertise and insights from early stages of development through commercialisation and the full lifecycle.

As part of ProductLife Group, an international leader in the life sciences industry, Commercial Eyes has expanded its global presence, enabling broader market access and expertise across the JAPAC region and beyond.

www.commercialeyes.com.au

ProductLife Group (PLG) acquires HERAX Life Science

ADMINUSER — Mon, 24 Feb 2025 05:00:00 GMT

Paris, France - 24.02.2025 ProductLife Group (PLG), a global leader in regulatory, scientific, compliance, and digital transformation consulting for the life sciences industry, is pleased to announce the acquisition of HERAX Life Science, a leading Danish business and technology consultancy providing tailored services and solutions for the life sciences industry.

Founded in Copenhagen in 2009, HERAX Life Science has established itself as a highly specialized business and IT consultancy, supporting life sciences companies in digitizing R&D activities, selecting and delivering technology solutions, and optimizing business processes within clinical development. Supported by a team of industry experts, HERAX Life Science leverages methodology, deep process understanding and technology to help clients enhance their R&D efforts and achieve better outcomes. This acquisition unites HERAX Life Science and PLG under a shared commitment to accelerate drug development, streamline clinical trials, and ensure the highest standards of safety and compliance.

While PLG has already established a strong presence in the Nordics since the acquisition of Pharma IT in 2022, this new alliance marks a significant step in PLG’s strategy to build a fully integrated regional and global platform.

Allan Bech Thomsen, CEO of HERAX Life Science added:

“Joining PLG is a strategic move, for the company, its people and clients. With PLG as our catalyst, we will be able to accelerate our international expansion.

We will leverage our boutique approach in order to better support local and international customers with effective consultancy and transformational digital services dedicated to GxP regulated areas of the life sciences. PLG is a perfect match for ensuring continuous success of HERAX Life Science while sharing our common purpose and values.”

Xavier Duburcq, CEO of PLG, commented:

“The acquisition of HERAX is a major step to expand our expertise and accelerate digital transformation for PLG’s global clients. Thanks to this combination with HERAX Life Sciences, we have now a team of 300 seasoned data and technology professionals, adept in Regulatory Affairs, Quality, Safety, Clinical, Laboratory and other critical areas along the R&D value chain, providing tailored solutions that align with our clients’ challenges. This is unique in Europe.”

About ProductLife Group: ProductLife Group’s mission is to support patient access to safe and effective healthcare solutions by delivering worldwide consulting and outsourcing services through the entire product life. Combining local expertise with global reach spanning more than 150 countries, PLG is the Life Sciences Industry reference strategic partner for the development, market introduction and life cycle management of product portfolios, and the related business and digital transformation. With a goal of continuously improving the value delivered to teams and clients, PLG is committed to long-term partnership, innovation, flexibility, and cost efficiency.

For more information, visit https://plglifesciences.com/

Contact: Fabrice Galzin ProductLife Group Head of Marketing fgalzin@productlife-group.com

About HERAX Life Science

HERAX Life Science is a specialized high-end life science business and IT consultancy helping life science companies digitize and optimize their activities in clinical development.

The firm comprises a diverse team of consultants with deep knowledge and extensive experience in the life sciences industry. HERAX Life Science has 30 consultants who are subject matter experts in various R&D areas, collectively driving projects with dedication and adding value to their clients' initiatives.

For more information,
visit https://herax.com/

Contact:

Allan Bech Thomsen
Chief Executive Officer
abt@herax.com

ProductLife Group (PLG) Acquires Stragen Services

ADMINUSER — Tue, 28 Jan 2025 05:00:00 GMT

Paris, France –28.01.2025 ProductLife Group (PLG), a global provider of regulatory, scientific, compliance, and digital transformation consulting services for the life sciences industry, is pleased to announce the acquisition of Stragen Services, a division of Stragen Group, a well-established European Specialty Generics platform backed by healthcare-focused global private equity firm ARCHIMED.

Founded in 2009 and located in Lyon, France, Stragen Services is a recognized partner to the Pharma and Biotech communities in the fields of Pharmacovigilance and Clinical Safety services. With a team of 36 employees, Stragen Services has earned a reputation for its strong expertise and tailored pharmacovigilance support services. By bringing Stragen Services into the PLG fold, the Group will expand in these critical areas, supporting PLG’s continuous goal of ensuring the access, compliance and safety of products across global markets.

Stéphanie Collomb Gilbert, General Manager of Stragen Services , commented: "Joining PLG is a strategic and exciting step for Stragen Services, our team, and our clients. PLG’s commitment to excellence, integrity, and client-focused partnerships mirrors our values. This alliance strengthens our ability to deliver top-notch international safety solutions and better support our clients in combination with PLG’s integrated global infrastructure. As the needs for innovation and global expertise grow, we are eager to expand our reach and make an even bigger impact together.”

Xavier Duburcq, CEO of PLG, highlighted: "We are thrilled to welcome Stragen Services to the PLG family. This acquisition represents a key milestone in our growth journey, consolidating our pharmacovigilance leadership across the French and European market. It underscores our commitment to providing clients with world-class support, ensuring their products meet the highest standards of safety and compliance in an increasingly complex global landscape. Stragen Services’ track record and expertise will play a pivotal role in fortifying our industry position and further aligns with our ambition."

Jean-Yves Desmottes, Partner at ARCHIMED: “Initially set up to support the pharmacovigilance activities of Stragen Group, Stragen Services grew over the last 15 years extending its expertise while offering its services to multiple customers outside the Stragen environment. PLG represents a great opportunity for all its employees to continue this journey, uphold standard of excellence, expand services offering and ultimately support the next phase of growth.“

About ProductLife Group: ProductLife Group’s mission is to support patient access to safe and effective healthcare solutions by delivering worldwide consulting and outsourcing services through the entire product life. Combining local expertise with global reach spanning more than 150 countries, PLG is the Life Sciences Industry reference strategic partner for the development, market introduction and life cycle management of product portfolios, and the related business and digital transformation. With a goal of continuously improving the value delivered to teams and clients, PLG is committed to long-term partnership, innovation, flexibility, and cost efficiency.

For more information, visit https://plglifesciences.com/

Contact: Fabrice Galzin ProductLife Group Head of Marketing fgalzin@productlife-group.com

About Stragen Services Stragen Services is a leading consultancy located in Lyon, France, and offering tailored Pharmacovigilance and Clinical Safety services to the Pharma, Biotech and Medtech industries. Founded in 2009, Stragen Services combines safety regulatory expertise with a client-focused approach to support local and some regional needs across +10 therapeutic areas. With a team of highly skilled physicians, pharmacists, and scientists, Stragen Services delivers customized solutions that meet the highest industry standards, ensuring clients achieve their strategic objectives in a complex and evolving healthcare landscape.

For more information, visit https://www.stragen-services.fr/
Contact: Stéphanie Collomb Gilbert General Manager s.collombgilbert@stragen.fr

ProductLife Group acquires Calliso in the UK

fgalzin — Wed, 30 Oct 2024 04:00:00 GMT

Paris, France – 30.10.2024 ProductLife Group (PLG), a global leader in regulatory, scientific, compliance, and digital transformation consulting services for the life sciences industry, is excited to announce the acquisition of Callisto, a leading UK-based consultancy specializing in Regulatory Affairs (RA), Pharmacovigilance (PV) and GMDP services within multiple regulated sectors including human and veterinary medicines, medical devices, and borderline products.

Founded in 2003, Callisto has a strategic geographical presence in both the UK and Ireland and serves more than a hundred clients, with over 85% repeat business, demonstrating their commitment to delivering exceptional client service.

Originally serving clients from its UK base, Callisto expanded operations in 2018 by opening an affiliate in Dublin, to ensure seamless EU regulatory, GMP and pharmacovigilance services following Brexit.

This acquisition further enhances PLG’s presence in the UK, following the recent acquisition of Integrity. With 37 people and offices in Lockington, Derbyshire (England) and Dublin (Ireland), Callisto’s services perfectly align with PLG’s core business areas, allowing for significant synergies and growth opportunities. The combined capabilities of PLG and Callisto enable end-to-end regulatory solutions designed to streamline development, market entry, and compliance strategies across global markets.

Callisto’s Managing Director and one of the original founders, Joanne Bunyan, commented: "This partnership marks a new important milestone in our growth journey. As Callisto integrates with PLG, we are forging a powerful alliance in the regulatory arena, bringing our regulatory, GMP and compliance expertise to a broader audience, while still delivering high-quality service to our clients in the UK and Europe."

Xavier Duburcq, CEO of PLG, added: "PLG and Callisto joining forces offers great potential to our complementary client bases and will contribute to the successful development of our operations and business in the UK. Our positive cultures and values are very well-matched and expanding PLG in this region with the similarly motivated team at Callisto should bring exciting opportunities for all.”

About ProductLife Group:

ProductLife Group’s mission is to support patient access to safe and effective healthcare solutions by delivering worldwide consulting and outsourcing services through the entire product life. Combining local expertise with global reach spanning more than 150 countries, PLG is the Life Sciences Industry reference strategic partner for the development, market introduction and life cycle management of product portfolios, and the related business and digital transformation. With a goal of continuously improving the value delivered to teams and clients, PLG is committed to long-term partnership, innovation, flexibility, and cost efficiency.

For more information, visit https://productlifegroup.com/
Contact:
Fabrice Galzin
ProductLife Group Head of Marketing
fgalzin@productlife-group.com

About Callisto

Founded in 2003 as Callisto Regulatory Consulting Ltd, Callisto Pharma Group has evolved into a comprehensive consultancy providing a full range of technical services across the entire supply chain within multiple regulated sectors, including human, veterinary and herbal medicines, borderline products, biocides, medical devices, and food supplements.

Callisto works with clients across the UK, Europe and globally, supporting businesses in highly regulated industries—from global multi-nationals to single product licence holders. The group offers product release and QP technical support to manufacturers and licence holders, holding MIA’s and ManA/VIA granted by both the MHRA and HPRA, allowing them to assist clients in importing licensed and unlicencesd human and veterinary products into the UK and Europe.

For more information, visit https://www.callistopharmagroup.com/
Contact:
Paul Bunyan
Operations Director
paul@callistopharmagroup.com

ProductLife Group acquires Halloran in USA

fgalzin — Wed, 16 Oct 2024 04:00:00 GMT

BOSTON; Oct. 16, 2024 (Business Wire) – ProductLife Group (PLG), a trusted global leader in regulatory, scientific, compliance, and digital transformation consulting services for the life sciences, today announced the acquisition of Halloran Consulting Group, a life science consulting firm that provides strategic regulatory, quality, clinical, and organizational support in the pharmaceutical, biotechnology, and medical device sectors in the United States, further positioning PLG as a leading global provider of comprehensive healthcare services.